This is an open-label study to investigate the efficacy and safety of ABBV-668 in patients with moderate to severe UC. The study contains a 30-day screening period, 16-week treatment period, and a 30-day follow up period from the last dose of study drug.
Criteria:• Are 18 years of age or older
• Diagnosis of Ulcerative Colitis at least 90 days prior to study start. Appropriate documentation of biopsy results consistent with the diagnosis of UC in the assessment of the Investigator, must be available
• Active Ulcerative Colitis with an Adapted Mayo score of 5 to 9 points and Endoscopic Subscore of 2 to 3
• Demonstrated inadequate response to, loss of response to, or intolerance to at least one of the following: oral aminosalicylates, corticosteroids, immunosuppressants and/or biologics or targeted immunomodulators
• No extent of inflammatory disease limited to the rectum as assessed by screening endoscopy
• No current diagnosis of CD or inflammatory bowel disease-unclassified (IBD-U)
* Participants will be asked to take study drug twice per day, attend study visits, and comply with study activities.